Using rhDNase to reduce mortality in COVID-19 patients with respiratory failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 randomized placebo-controlled trial aims to evaluate the safety and efficacy of nebulized Dornase Alpha (rhDNase) in reducing 28-day mortality among COVID-19 patients experiencing respiratory failure. Participants will include adults requiring high-flow oxygen or mechanical ventilation, and they will be randomly assigned to receive either the treatment or a placebo. The study will assess the impact of rhDNase on patient outcomes over a specified period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or Female age 18 or older
2. On high flow oxygen =/\> 6 liters nasal cannula (or)
3. On mechanical ventilation
4. Clinical diagnosis of COVID-19 \& positive PCR test (or)
5. Clinical diagnosis of COVID-19 \& negative PCR test with clinical symptoms of COVID-19 and pathognomonic lesions on a chest CT scan

Exclusion Criteria:

1. Known allergy to Pulmozyme
2. Less than 18 years of age
3. Grave condition with anticipated death within 48 hours; at the discretion of treating physician.
4. Enrollment in another clinical trial receiving investigatory drugs

Where it's running

• University of South Alabama
  Mobile, Alabama, United States Recruiting

Study contacts

• Study coordinator: Jon D Simmons, M.D.
• Email: jdsimmons@health.southalabama.edu
• Phone: 12514459834

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating olfactory dysfunction after COVID-19 infection

  This study is trying to understand why some people still have trouble smelling after recovering from COVID-19 by looking at samples from their noses.

  Recruiting at 6 sites Universitaire Ziekenhuizen KU Leuven · Brussels, Brussels Capital and 6 other locations · NCT06482138

• Registry to evaluate pregnancy outcomes in women treated for COVID-19

  This study is trying to see how treatments for COVID-19, like certain medications, affect the health of pregnant women and their babies.

  Recruiting Pregistry · Los Angeles, California · NCT05013632

• Collecting COVID-19 virus secretions and serum for developing treatments

  This study is collecting samples from people with COVID-19 to learn more about how the virus behaves and how it affects recovery, with the goal of improving treatments for those at higher risk.

  Recruiting at 2 sites Tulane University · New Orleans, Louisiana and 1 other locations · NCT04956445

• Using donor-derived T cells to treat mild to moderate COVID-19

  This study is testing whether T cells from family members who have recovered from COVID-19 can help treat hospitalized patients with mild to moderate COVID-19.

  Recruiting Phase 1/2 New York Medical College · Valhalla, New York and 3 other locations · NCT04896606

• Observational study on the biology of COVID-19 in Saarland

  This study looks at how COVID-19 affects people in different ways, including those with long-term symptoms, to learn more about the disease and its progression.

  Recruiting Universität des Saarlandes · Homburg, Saarland · NCT04837755

• Imaging immune activation in COVID-19 patients

  This study is testing a special imaging technique to see how the immune system is working in people who have recently recovered from COVID-19.

  Recruiting Phase 2 CellSight Technologies, Inc. · San Francisco, California · NCT04815096

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.